{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:21:14Z","timestamp":1782904874047,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This research received no funding."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01786-w","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:49:40Z","timestamp":1751604580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Potential therapeutic roles of natural killer cells in acute myeloid leukemia: a systematic review study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-0237","authenticated-orcid":false,"given":"Mohammad","family":"Khani-Eshratabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-0303","authenticated-orcid":false,"given":"Jamal","family":"Motallebzadeh Khanmiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-4656","authenticated-orcid":false,"given":"Mohammad Reza","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8651-0240","authenticated-orcid":false,"given":"Zeinab","family":"Moradi Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1081-3944","authenticated-orcid":false,"given":"Amirreza","family":"Daei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9614-4077","authenticated-orcid":false,"given":"Mohaddeseh","family":"Hedayat Hasanabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3970-4319","authenticated-orcid":false,"given":"Simin","family":"Saberi Amarghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5439-7885","authenticated-orcid":false,"given":"Nazanin","family":"Younesi Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-6795","authenticated-orcid":false,"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"6","key":"1786_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1365-2141.2009.07684.x","volume":"145","author":"W Ingram","year":"2009","unstructured":"Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, et al. Human CD80\/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. Br J Haematol. 2009;145(6):749\u201360.","journal-title":"Br J Haematol"},{"issue":"1","key":"1786_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","volume":"23","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H, et al. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer. 2023;23(1):1090.","journal-title":"BMC Cancer"},{"issue":"11","key":"1786_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","volume":"139","author":"JJ Bednarski","year":"2022","unstructured":"Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022;139(11):1670\u201383.","journal-title":"Blood"},{"issue":"13","key":"1786_CR4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2018-09-874990","volume":"133","author":"A Hallner","year":"2019","unstructured":"Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, et al. The HLA-B\u2212 21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood. 2019;133(13):1479\u201388.","journal-title":"Blood"},{"issue":"29","key":"1786_CR5","doi-asserted-by":"publisher","first-page":"46466","DOI":"10.18632\/oncotarget.10191","volume":"7","author":"A Cuapio","year":"2016","unstructured":"Cuapio A, Post M, Cerny-Reiterer S, Gleixner KV, Stefanzl G, Basilio J, et al. Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. Oncotarget. 2016;7(29):46466.","journal-title":"Oncotarget"},{"issue":"4","key":"1786_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1600-0609.1999.tb01886.x","volume":"63","author":"M Hokland","year":"1999","unstructured":"Hokland M, J\u00f8rgensen H, Holm MS, Simonsson B, Nilsson B, Bengtsson M, et al. Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator Linomide after autologous bone marrow transplantation. Eur J Haematol. 1999;63(4):251\u20138.","journal-title":"Eur J Haematol"},{"issue":"6","key":"1786_CR7","doi-asserted-by":"publisher","first-page":"e0123416","DOI":"10.1371\/journal.pone.0123416","volume":"10","author":"PD Kottaridis","year":"2015","unstructured":"Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, et al. Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase I trial. PLoS ONE. 2015;10(6):e0123416.","journal-title":"PLoS ONE"},{"issue":"8","key":"1786_CR8","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al. Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin Cancer Res. 2018;24(8):1834\u201344.","journal-title":"Clin Cancer Res"},{"key":"1786_CR9","doi-asserted-by":"publisher","first-page":"804988","DOI":"10.3389\/fimmu.2021.804988","volume":"12","author":"S Parisi","year":"2022","unstructured":"Parisi S, Ruggeri L, Dan E, Rizzi S, Sinigaglia B, Ocadlikova D, et al. Long-term outcome after adoptive immunotherapy with natural killer cells: alloreactive NK cell dose still matters. Front Immunol. 2022;12:804988.","journal-title":"Front Immunol"},{"issue":"357","key":"1786_CR10","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.","journal-title":"Sci Transl Med"},{"issue":"25","key":"1786_CR11","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","volume":"123","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123(25):3855\u201363.","journal-title":"Blood"},{"key":"1786_CR12","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8183","author":"Y Zeng","year":"2021","unstructured":"Zeng Y, Lv X, Du J. Natural killer cell-based immunotherapy for lung cancer: challenges and perspectives (Review). Oncol Rep. 2021. https:\/\/doi.org\/10.3892\/or.2021.8183.","journal-title":"Oncol Rep"},{"issue":"20","key":"1786_CR13","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1158\/0008-5472.CAN-23-1097","volume":"83","author":"S Ma","year":"2023","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing natural killer cells for lung cancer therapy. Cancer Res. 2023;83(20):3327\u201339.","journal-title":"Cancer Res"},{"issue":"12","key":"1786_CR14","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.ymthe.2021.06.018","volume":"29","author":"E Chiu","year":"2021","unstructured":"Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K, et al. Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Mol Ther. 2021;29(12):3410\u201321.","journal-title":"Mol Ther"},{"issue":"22","key":"1786_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood.V128.22.1649.1649","volume":"128","author":"M Boyiadzis","year":"2016","unstructured":"Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou J-Z, et al. Phase 1 clinical trial of adoptive immunotherapy using\" Off-the-Shelf\" activated natural killer cells (aNK) in patients with refractory\/relapsed acute myeloid leukemia. Blood. 2016;128(22):1649.","journal-title":"Blood"},{"issue":"8","key":"1786_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","volume":"22","author":"A Curti","year":"2016","unstructured":"Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, et al. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res. 2016;22(8):1914\u201321.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1786_CR17","doi-asserted-by":"publisher","first-page":"e2122379119","DOI":"10.1073\/pnas.2122379119","volume":"119","author":"H Dong","year":"2022","unstructured":"Dong H, Ham JD, Hu G, Xie G, Vergara J, Liang Y, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci. 2022;119(25):e2122379119.","journal-title":"Proc Natl Acad Sci"},{"issue":"15","key":"1786_CR18","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","volume":"23","author":"H Dolstra","year":"2017","unstructured":"Dolstra H, Roeven MW, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, et al. Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin Cancer Res. 2017;23(15):4107\u201318.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1786_CR19","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/cancers13112673","volume":"13","author":"R Devillier","year":"2021","unstructured":"Devillier R, Calmels B, Guia S, Taha M, Fauriat C, Mfarrej B, et al. Phase I trial of prophylactic donor-derived IL-2-activated NK cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor. Cancers. 2021;13(11):2673.","journal-title":"Cancers"},{"issue":"9","key":"1786_CR20","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1158\/2326-6066.CIR-17-0711","volume":"6","author":"E Bernson","year":"2018","unstructured":"Bernson E, Hallner A, Sander F, Nicklasson M, Nilsson M, Christenson K, et al. Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. Cancer Immunol Res. 2018;6(9):1110\u20139. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0711.","journal-title":"Cancer Immunol Res"},{"key":"1786_CR21","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"issue":"1","key":"1786_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"1786_CR23","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"2","key":"1786_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/eb-2014-101794","volume":"17","author":"A Nikolakopoulou","year":"2014","unstructured":"Nikolakopoulou A, Mavridis D, Salanti G. How to interpret meta-analysis models: fixed effect and random effects meta-analyses. Evid Based Ment Health. 2014;17(2):64.","journal-title":"Evid Based Ment Health"},{"issue":"10","key":"1786_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","volume":"19","author":"M Boyiadzis","year":"2017","unstructured":"Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou J-Z, et al. Phase 1 clinical trial of adoptive immunotherapy using \u201cOff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017;19(10):1225\u201332.","journal-title":"Cytotherapy"},{"issue":"13","key":"1786_CR26","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","volume":"3","author":"S Cooley","year":"2019","unstructured":"Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Adv. 2019;3(13):1970\u201380.","journal-title":"Blood Adv"},{"issue":"12","key":"1786_CR27","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","volume":"118","author":"A Curti","year":"2011","unstructured":"Curti A, Ruggeri L, D\u2019Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118(12):3273\u20139.","journal-title":"Blood"},{"issue":"8","key":"1786_CR28","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","volume":"24","author":"TA Fehniger","year":"2018","unstructured":"Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, et al. A phase 1 trial of CNDO-109\u2013activated natural killer cells in patients with high-risk acute myeloid leukemia. Biol Blood Marrow Transpl. 2018;24(8):1581\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"1786_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.clml.2021.01.013","volume":"21","author":"LMG Garc\u00eda","year":"2021","unstructured":"Garc\u00eda LMG, Escudero A, Mestre C, Soler JLF, Mart\u00ednez AP, Valero JMV, et al. Phase 2 clinical trial of infusing haploidentical K562-mb15\u201341BBL\u2013activated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(5):328-37.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"1786_CR30","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"1","key":"1786_CR31","doi-asserted-by":"publisher","first-page":"e029642","DOI":"10.1136\/bmjopen-2019-029642","volume":"10","author":"MM Builes","year":"2020","unstructured":"Builes MM, Cuenca MV, Soler JLF, Astigarraga I, Mart\u00ednez AP, Valero JMV, et al. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. BMJ Open. 2020;10(1):e029642.","journal-title":"BMJ Open"},{"key":"1786_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0564-6","volume":"7","author":"R Nguyen","year":"2019","unstructured":"Nguyen R, Wu H, Pounds S, Inaba H, Ribeiro RC, Cullins D, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7:1\u20137.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1786_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/imt-2019-0108","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yang J, Zhang G, Song L, Su Y, Shi Y, et al. 5 Years of clinical DC-CIK\/NK cells immunotherapy for acute myeloid leukemia \u00e2\u20ac\u201c\u00c2 a summary. Immunotherapy. 2020;12(1):63\u201374.","journal-title":"Immunotherapy"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01786-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:29Z","timestamp":1764917429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01786-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01786-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"233"}}